Key result
Renal denervation significantly reduced the index of enhancement of the main renal artery wall from 1.7 to 1.4 (p=0.02) at 12 months in diabetic patients with resistant hypertension.
Why the study?
The study aimed to investigate the long-term effect of renal denervation on MRI characteristics of the renal artery wall in diabetic patients with resistant hypertension.
Does renal denervation improve MRI-characteristics of the renal artery wall and reduce systemic inflammation in diabetic patients with resistant hypertension?
RCT (n=19)
Double-blind
1:1
No
Does renal denervation improve MRI-characteristics of the renal artery wall and reduce systemic inflammation in diabetic patients with resistant hypertension?
Absolute Event Rate: 1.4% vs 1.7%
p-value: p=0.02
Renal denervation in diabetic patients with resistant hypertension reduces blood pressure and attenuates MRI signs of vascular wall damage, which correlates with a reduction in systemic subclinical inflammation.
May attenuate renal artery wall enhancement in diabetic resistant hypertension; hypothesis-generating pending randomized confirmation.
Objective . The aim of this study was to investigate the long-term effect of renal denervation (RDN) on MRIcharacteristics of renal artery (RA) wall in diabetic patients with resistant hypertension (RHTN). Design and methods . We included 19 diabetic patients with RHTN (mean age 61,9 ± 6,8 years; 6 men; HbA1c 6,6 ± 1,4 %; mean blood pressure (BP) 24h 159,5 ± 18,9 / 82,2 ± 13,7 mm Hg) who underwent MRI of the RA before and 12 months after RDN. The measurement of signal intensity (SI) of RA wall based on two-dimensional T1-weighted spin-echo images was done before and after the administration of a gadolinium-based contrast agent. The index of enhancement (IE) was calculated as ratio of SI post-to-precontrast enhancement. All patients underwent ambulatory 24-hour (24h) BP monitoring, lab tests (serum hsC-reactive protein (CRP), tumor necrosis factoralpha (TNF-α)) at baseline and 12-month follow-up. On average, patients were taking 4 (3–6) antihypertensive drugs. The mean number of ablations was 13 ± 1,8 (10–16). Patients were instructed not to change the treatment regimen throughout the study. At 12-month follow up MRI of RA was available for 16 patients. Results . After RDN there was a significant comparable decrease in IE of RA wall for both sides (IE mean values for right and left sides: from 1,7 ± 0,4 to 1,4 ± 0,3, p = 0,02 for the main RA; from 1,7 ± 0,5 to 1,4 ± 0,2, p = 0,04 for the middle parts of RA; from 1,9 ± 0,4 to 1,4 ± 0,3, p = 0,001 for distal branches of RA). In addition, RDN reduced the 24h BP (systolic / diastolic) by –15,1/–10,0 mm Hg, p < 0,001 as well as reduced the level of TNF-α (from 4,6 ± 3,8 to 3,4 ± 2,5 pg/ml, p = 0,03) and the level of hsCRP (from 6,5 ± 3,4 to 5,9 ± 3,2mg/L, p = 0,003). There was no direct relation between the IE and BP reduction. At the same time, the change in IE of middle part of RA after RD was directly related to decrease in both hsCRP level (R = 0,62, p = 0,03) and TNF-α level (R = 0,56, p = 0,04). Conclusions . The beneficial effect of RDN on the RA wall is associated with the attenuation of systemic subclinical inflammation.
No takes yet. Share an insight, caveat, or question.
Falkovskaya et al. (2020) conducted an RCT in Resistant hypertension with type 2 diabetes mellitus (n=19). Renal denervation vs. Baseline (pre-intervention) was evaluated on Index of enhancement (IE) of the main renal artery wall on contrast-enhanced MRI (p=0.02). Renal denervation significantly reduced the index of enhancement of the main renal artery wall from 1.7 to 1.4 (p=0.02) at 12 months in diabetic patients with resistant hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: